
PBYI
Healthcare · Biotechnology · $401.7M market cap
$7.77-0.31 (-3.8%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · -36.8% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 5, 2026 | After the close | 0.06 | 0.11 | +83.3% |
| Aug 6, 2026 | After the close | 0.06 | 0.16 | +166.7% |
| May 7, 2026 | After the close | -0.13 | -0.04 | +69.2% |
| Feb 26, 2026 | Time not confirmed | 0.19 | 0.26 | +36.8% |
| Nov 6, 2025 | After the close | 0.09 | 0.21 | +133.3% |
| Aug 7, 2025 | After the close | 0.08 | 0.12 | +50.0% |
| May 8, 2025 | After the close | -0.02 | 0.06 | +400.0% |
| Feb 26, 2025 | Before the open | 0.14 | 0.43 | +207.1% |
| Nov 7, 2024 | After the close | 0.38 | 0.45 | +18.4% |
| Aug 1, 2024 | After the close | -0.10 | -0.05 | +50.0% |
| May 2, 2024 | After the close | -0.15 | -0.05 | +66.7% |
| Feb 29, 2024 | After the close | 0.30 | 0.26 | -13.3% |
| Nov 2, 2023 | After the close | 0.14 | 0.17 |
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The…
| +21.4% |
| Aug 3, 2023 | After the close | 0.07 | 0.10 | +42.9% |
| May 4, 2023 | After the close | -0.01 | 0.09 | +1000.0% |
| Mar 2, 2023 | After the close | 0.01 | -0.12 | -1300.0% |
| Nov 3, 2022 | After the close | 0.03 | 0.05 | +66.7% |
| Aug 4, 2022 | After the close | 0.09 | 0.28 | +211.1% |
| May 5, 2022 | After the close | -0.11 | -0.01 | +90.9% |
| Mar 3, 2022 | After the close | -0.09 | 0.10 | +211.1% |
| Nov 4, 2021 | After the close | -0.22 | -0.99 | -350.0% |
| Aug 5, 2021 | After the close | -0.14 | 0.32 | +328.6% |
| May 6, 2021 | After the close | 0.34 | 0.55 | +61.8% |
| Feb 25, 2021 | After the close | -0.31 | -0.38 | -22.6% |
| Nov 5, 2020 | After the close | -0.14 | -0.60 | -328.6% |
| Aug 6, 2020 | After the close | 0.14 | 0.35 | +150.0% |
| May 7, 2020 | After the close | -0.68 | -0.20 | +70.6% |
| Feb 20, 2020 | After the close | -0.26 | 0.01 | +103.8% |
| Nov 6, 2019 | After the close | -0.45 | -0.12 | +73.3% |
| Aug 8, 2019 | After the close | -0.89 | -0.57 | +36.0% |
| May 9, 2019 | After the close | -0.20 | 0.20 | +200.0% |
| Feb 28, 2019 | After the close | -0.77 | -0.80 | -3.9% |
| Nov 1, 2018 | After the close | -0.45 | 0.16 | +135.6% |
| Aug 9, 2018 | After the close | -0.82 | -0.59 | +28.0% |
| May 9, 2018 | After the close | -0.31 | 0.02 | +106.5% |
| Mar 1, 2018 | After the close | -1.97 | -1.71 | +13.2% |